

April 11, 2022

BrightPath Presents New Data on Personalized Neoantigen Vaccine at AACR 2022

- *New data highlighting scientific advancements in immune-checkpoint antibody-directed personalized neoantigen vaccine, BP1209.*

Tokyo, Japan - April 11, 2022/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that preclinical data on BP1209(Personalized neoantigen vaccine) at the American Association for Cancer Research Annual Meeting (“AACR 2022”) on April 8-13. The abstract featuring data on a new platform for personalized neoantigen vaccine, BP1209 will be shared in a virtual poster viewing session.

BrightPath’s abstract is as follows:

TTitle: A novel computational pipeline supported with in vivo T cell induction data for identification and validation of neoantigens (6389)

Kazushi Hiranuka at BrightPath Biotherapeutics

The abstract for this presentation is available on the websites of the [AACR](#) and [BrightPath](#).

We have developed a robust computational pipeline to identify putatively actionable neoantigens from patients’ WES and RNA-Seq data. We generated NGS data from over 100 clinical samples and analyzed the data using our computational pipeline. From 27 patient cases, 275 of HLA-A02:01-, A24:02-, B07:02-, or B35:01-predicted neoantigen epitopes were tested in HLA transgenic mice and confirmed that the rate of positively reacted epitopes increased in a correlated manner to the prediction score. We further developed an immunogenicity prediction model trained with these experimental results and tested its performance in additional clinical samples. By integrating it into the selection criteria, we achieved higher positive rate.

About BrightPath:

BrightPath Biotherapeutics is an immuno-oncology focused biotech company dedicated to improving treatment and clinical outcomes for patients through cancer vaccine, therapeutic antibodies, and cell therapy that harness the immune system to fight cancer.

BrightPath’s clinical-stage product, GRN-1201 is a new cancer vaccine in phase 2 trial in patients with melanoma and lung cancer in US. BP2201 in-collaboration with RIKEN, Japan is

an iPS (induced pluripotent stem cell)-derived NKT therapy and the phase 1 trial is currently ongoing in Japan.

BrightPath's broad pipeline of immunotherapy includes several potentially first-in-class and best-in-class clinical and preclinical candidates in cancers with high unmet medical need.

BrightPath has been a pioneer in immunotherapy by cancer vaccine and has expanded its expertise in the tumor microenvironment and immune cell development as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio of cancer vaccine, therapeutic antibody, and immune-cell therapy.

Based in Tokyo, Japan, BrightPath is listed on Tokyo Stock Exchange in Japan. For more information, visit www.brightpathbio.com

Forward-Looking Statements:

This news release contains forward-looking statements that are based on the current expectations and beliefs of BrightPath. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. BrightPath cautions that these forward-looking statements do not guarantee our future financial results but involve risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. These forward-looking statements speak only as of the date of this press release and BrightPath assumes no duty to update forward-looking statements, except as may be required by law.

Investor and Media Contact:

+81-3-5840-7697

irpr@brightpathbio.com

www.brightpathbio.com